Pharmacologic Therapy in Men's Health: Hypogonadism, Erectile Dysfunction, and Benign Prostatic Hyperplasia.

Kathryn E Berkseth, Arthi Thirumalai, John K Amory

Journal: The Medical clinics of North America 2017;100(4):791-805

PMID: 27235615

Free Full Text on PubMed Central View on PubMed

Abstract

This article reviews current pharmacologic treatment options for 3 common men's health concerns: hypogonadism, erectile dysfunction (ED), and benign prostatic hyperplasia (BPH). Specific topics addressed include: management of male hypogonadism using testosterone replacement therapy, use of oral phosphodiesterase inhibitors as first-line therapy for men with ED and the utility of intraurethral and intrapenile alprostadil injections for patients who do not respond to oral medications, and the role of alpha1-adrenergic antagonists, 5-alpha-reductase inhibitors, anticholinergic agents, and herbal therapies in the management of BPH.

Address: Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, 1959 Northeast Pacific Street, Box 356426, Seattle, WA 98195, USA. Electronic address: [email protected].; Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, 1959 Northeast Pacific Street, HSB C-209, UW Box# 357138, Seattle, WA 98195, USA.; Department of Medicine, University of Washington, 4245 Roosevelt Way Northeast, Box #354760, Seattle, WA 98105, USA.

DOI: 10.1016/j.mcna.2016.03.006

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/enlargedprostatebph.html

Other Literature Sources:

https://scite.ai/reports/27235615

Subscription / membership required

Full Text Sources:

MeSH Terms: 5-alpha Reductase Inhibitors, Drug Administration Routes, Drug Therapy, Combination, Erectile Dysfunction, Humans, Hypogonadism, Male, Men's Health, Phosphodiesterase Inhibitors, Prostatic Hyperplasia, Testosterone